Security
AbCellera Biologics Inc. Common Shares · ABCL
ABCLNASDAQCommon stockCurrentCIK 1703057Updated Oct 6, 2026
ABCL price & chart
Loading TradingView…
NASDAQ:ABCL on TradingView ↗About the company
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.
In the news
These Have the Market Hot Zone Catalysts and Setups ↗
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 ↗
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile ↗
Recent filings
4 filing
4 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
4 filing
Show 5 more recent filings
424B5 filing
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,355,992,000Source | 1,392,828,000Source | 1,307,575,000Source | 1,402,061,000Source | 1,412,481,000Source | 1,307,112,000Source | 1,344,208,000Source | 1,463,096,000Source | 1,356,950,000Source | 1,360,553,000Source | 1,488,094,000Source | 1,540,907,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 217,255,000Source |
| GoodwillUSD | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 39,321,000Source | 52,577,000Source | 36,530,000Source | 40,262,000Source | 85,661,000Source | 37,460,000Source | 41,192,000Source | 118,736,000Source | 38,381,000Source | 42,113,000Source | 120,425,000Source | 131,502,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueCAD | 83,159,000Source | 126,640,000Source | 120,065,000Source | 92,437,000Source | 148,312,000Source | 77,063,000Source | 159,266,000Source | 123,572,000Source | 61,800,000Source | 55,600,000Source | 52,200,000Source | 44,900,000Source |
| Inventory, NetUSD | — | — | 7,578,000Source | — | — | 7,860,000Source | — | — | 6,336,000Source | — | — | — |
| Assets, CurrentUSD | 695,140,000Source | 742,883,000Source | 679,230,000Source | 742,145,000Source | 771,554,000Source | 664,596,000Source | 764,978,000Source | 813,948,000Source | 728,232,000Source | 751,370,000Source | 871,985,000Source | 1,025,491,000Source |
| Operating Lease, Right-of-Use AssetUSD | 137,914,000Source | 68,319,000Source | 131,822,000Source | 136,935,000Source | 70,156,000Source | 134,300,000Source | 68,736,000Source | 71,326,000Source | 136,117,000Source | 66,649,000Source | 73,141,000Source | — |
| Other Assets, NoncurrentUSD | 53,066,000Source | 134,215,000Source | 62,103,000Source | 57,454,000Source | 112,514,000Source | 69,136,000Source | 61,563,000Source | 104,933,000Source | 51,948,000Source | 96,538,000Source | 94,244,000Source | 46,331,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 391,954,000Source | 314,734,000Source | 411,555,000Source | 394,985,000Source | 301,513,000Source | 369,029,000Source | 321,226,000Source | 333,183,000Source | 390,046,000Source | 304,469,000Source | 335,776,000Source | 307,630,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 794,469,000Source | 772,832,000Source | 821,242,000Source | 791,668,000Source | 769,966,000Source | 816,533,000Source | 790,068,000Source | 764,562,000Source | 802,341,000Source | 777,171,000Source | 753,199,000Source | 734,365,000Source |
| Retained Earnings (Accumulated Deficit)USD | -20,537,000Source | 151,140,000Source | -128,074,000Source | 36,582,000Source | 202,247,000Source | -72,647,000Source | 71,309,000Source | 239,177,000Source | -29,482,000Source | 116,930,000Source | 279,787,000Source | 426,185,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,698,000Source | -1,232,000Source | -3,152,000Source | -2,657,000Source | -2,073,000Source | -2,419,000Source | -6,998,000Source | -1,816,000Source | -4,234,000Source | -4,378,000Source | -1,720,000Source | -1,391,000Source |
| Stockholders' Equity Attributable to ParentUSD | 964,038,000Source | 1,078,094,000Source | 896,020,000Source | 1,007,076,000Source | 1,110,968,000Source | 938,083,000Source | 1,022,982,000Source | 1,129,913,000Source | 966,904,000Source | 1,056,084,000Source | 1,152,318,000Source | 1,233,277,000Source |
| Additional Paid in Capital, Common StockUSD | 192,804,000Source | 155,354,000Source | 206,004,000Source | 181,483,000Source | 140,828,000Source | 196,616,000Source | 168,603,000Source | 127,990,000Source | 198,279,000Source | 166,361,000Source | 121,052,000Source | 74,118,000Source |
| Liabilities and EquityUSD | 1,355,992,000Source | 1,392,828,000Source | 1,307,575,000Source | 1,402,061,000Source | 1,412,481,000Source | 1,307,112,000Source | 1,344,208,000Source | 1,463,096,000Source | 1,356,950,000Source | 1,360,553,000Source | 1,488,094,000Source | 1,540,907,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 68,804,000Source | 79,568,000Source | 53,189,000Source | 67,023,000Source | 70,380,000Source | 47,294,000Source | 75,396,000Source | 104,883,000Source | 64,307,000Source | 76,612,000Source | 119,013,000Source | 118,320,000Source |
| Operating Lease, Liability, CurrentUSD | 5,166,000Source | 5,125,000Source | 5,669,000Source | 4,896,000Source | 5,603,000Source | 5,869,000Source | 4,637,000Source | 5,531,000Source | 5,815,000Source | 4,621,000Source | 6,158,000Source | 5,583,000Source |
| Operating Lease, Liability, NoncurrentUSD | 137,052,000Source | 66,274,000Source | 129,948,000Source | 137,184,000Source | 66,451,000Source | 134,309,000Source | 63,210,000Source | 68,079,000Source | 137,403,000Source | 60,743,000Source | 71,222,000Source | 76,675,000Source |
| Deferred Income Tax Liabilities, NetUSD | 9,744,000Source | 12,781,000Source | — | 10,053,000Source | 21,737,000Source | — | 10,053,000Source | 30,274,000Source | 9,115,000Source | 10,052,000Source | 30,612,000Source | 33,178,000Source |
| Other Liabilities, NoncurrentUSD | 1,386,000Source | 1,524,000Source | 9,714,000Source | 1,560,000Source | 6,348,000Source | 11,321,000Source | 1,624,000Source | 5,735,000Source | 4,768,000Source | 1,469,000Source | 5,906,000Source | 3,086,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 495,672,000Source | 643,139,000Source | 540,104,000Source | 553,078,000Source | 670,356,000Source | 504,732,000Source | 605,266,000Source | 698,023,000Source | 533,826,000Source | 625,614,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 9,115,000Source | 10,052,000Source | 29,798,000Source | 14,437,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -43,165,000Source | -45,621,000Source | -146,412,000Source | -162,857,000Source | -146,398,000Source | 158,519,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | —Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 12,013,000Source | 14,786,000Source | 55,792,000Source | 67,581,000Source | 64,183,000Source | 49,481,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 1,960,000Source | -2,114,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -33,523,000Source | -11,554,000Source | -131,295,000Source | -108,556,000Source | -43,877,000Source | 277,360,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -25,081,000Source | 7,935,000Source | 87,750,000Source | 121,409,000Source | -221,108,000Source | -352,625,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,831,000Source | 10,636,000Source | 42,772,000Source | 78,396,000Source | 76,947,000Source | 70,660,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,192,000Source | 5,970,000Source | 14,082,000Source | 12,769,000Source | 10,356,000Source | -1,628,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -51,450,000Source | 2,941,000Source | -28,366,000Source | 23,005,000Source | -254,040,000Source | -86,492,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 108,159,000Source | 151,640,000Source | 145,065,000Source | 117,437,000Source | 102,063,000Source | 184,266,000Source | 153,513,000Source | 181,325,000Source | 158,320,000Source | 411,535,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -38,000Source | 590,000Source | 1,097,000Source | -2,617,000Source | 589,000Source | -9,599,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 13,894,000Source | 17,164,000Source | 12,286,000Source | 14,208,000Source | 12,013,000Source | 14,786,000Source | 55,792,000Source | 67,581,000Source | 64,184,000Source | 49,481,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 920,000Source | 922,000Source | 3,700,000Source | 14,300,000Source | 11,600,000Source | 10,500,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 495,672,000Source | 643,139,000Source | 540,104,000Source | 553,078,000Source | 504,732,000Source | 605,266,000Source | 533,826,000Source | 625,614,000Source | — | — |
| DepreciationUSD | — | — | 4,300,000Source | 3,800,000Source | 6,100,000Source | 4,600,000Source | 5,918,000Source | 4,409,000Source | 18,439,000Source | 12,537,000Source | 12,758,000Source | 8,953,000Source |
| General and Administrative ExpenseUSD | — | — | 22,052,000Source | 19,147,000Source | — | 18,977,000Source | — | 16,226,000Source | 83,231,000Source | 72,711,000Source | 60,999,000Source | 55,485,000Source |
| GoodwillUSD | — | — | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source | 47,806,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 32,000,000Source | — | — | — | — | — | — | — | 8,400,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | 1,700,000Source | 1,800,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -11,649,000Source | -11,525,000Source | -3,538,000Source | -1,617,000Source | -6,372,000Source | -7,363,000Source | -31,183,000Source | -37,538,000Source | -27,631,000Source | 80,580,000Source |
| Investment Income, InterestUSD | — | — | 6,765,000Source | 9,603,000Source | — | 7,592,000Source | 3,643,000Source | 5,523,000Source | 28,329,000Source | 38,473,000Source | 42,247,000Source | 16,079,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | 800,000Source | 800,000Source | 2,100,000Source | 1,700,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -57,119,000Source | -51,107,000Source | -55,427,000Source | -34,727,000Source | -43,165,000Source | -45,621,000Source | -146,412,000Source | -162,857,000Source | -146,398,000Source | 158,519,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -57,119,000Source | -51,107,000Source | -55,427,000Source | -34,727,000Source | -43,165,000Source | -45,621,000Source | -146,412,000Source | -162,857,000Source | -146,398,000Source | 158,519,000Source |
| Nonoperating Income (Expense)USD | — | — | 7,510,000Source | 31,031,000Source | 3,812,000Source | 13,241,000Source | 7,982,000Source | 9,676,000Source | 39,508,000Source | 114,371,000Source | 63,178,000Source | 22,588,000Source |
| Operating ExpensesUSD | — | — | 85,233,000Source | 100,170,000Source | 66,827,000Source | 66,669,000Source | 65,834,000Source | 66,895,000Source | 292,231,000Source | 343,599,000Source | 275,232,000Source | 268,913,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 11,300,000Source | 9,100,000Source | 9,500,000Source | 7,100,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,984,000Source | 17,937,000Source | — | 1,957,000Source | — | -2,528,000Source | -2,711,000Source | 62,278,000Source | 6,776,000Source | -4,045,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Proceeds from Issuance of Long-term Debt | — | — | — | — | — | — | — | — | — | — | — | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 8,955,000Source | 6,507,000Source | 4,050,000Source | 17,084,000Source | 8,315,000Source | 4,235,000Source | 75,128,000Source | 28,833,000Source | 38,025,000Source | 485,424,000Source |
| Operating Income (Loss)USD | — | — | -76,278,000Source | -93,663,000Source | -62,777,000Source | -49,585,000Source | -57,519,000Source | -62,660,000Source | -217,103,000Source | -314,766,000Source | -237,207,000Source | 216,511,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,984,000Source | 17,937,000Source | — | 1,957,000Source | — | -2,528,000Source | -2,711,000Source | 62,278,000Source | 6,776,000Source | -4,045,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -68,768,000Source | -62,632,000Source | -58,965,000Source | -36,344,000Source | -49,537,000Source | -52,984,000Source | -177,595,000Source | -200,395,000Source | -174,029,000Source | 239,099,000Source |
| Income Tax Expense (Benefit)USD | — | — | -11,649,000Source | -11,525,000Source | -3,538,000Source | -1,617,000Source | -6,372,000Source | -7,363,000Source | -31,183,000Source | -37,538,000Source | -27,631,000Source | 80,580,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -57,119,000Source | -51,107,000Source | -55,427,000Source | -34,727,000Source | -43,165,000Source | -45,621,000Source | -146,412,000Source | -162,857,000Source | -146,398,000Source | 158,519,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.17Source | -0.18Source | -0.12Source | -0.14Source | -0.15Source | -0.49Source | -0.55Source | -0.51Source | 0.56Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.17Source | -0.18Source | -0.12Source | -0.14Source | -0.15Source | -0.49Source | -0.55Source | -0.51Source | 0.5Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 298,875,174Source | 294,851,945Source | 305,557,294Source | 298,508,601Source | 303,074,605Source | 297,692,663Source | 298,707,082Source | 294,327,532Source | 289,166,486Source | 285,056,606Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 298,875,174Source | 294,851,945Source | 305,557,294Source | 298,508,601Source | 303,074,605Source | 297,692,663Source | 298,707,082Source | 294,327,532Source | 289,166,486Source | 314,827,255Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 920,000Source | 922,000Source | 3,700,000Source | 14,300,000Source | 11,600,000Source | 10,500,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -30,245,000Source | -17,789,000Source | -29,591,000Source | 82,692,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 5,247,000Source | 36,919,000Source | — | 5,470,000Source | — | 5,331,000Source | — | — | 24,395,000Source | — |
| General and Administrative ExpenseUSD | — | — | 22,052,000Source | 19,147,000Source | — | 18,977,000Source | — | 16,226,000Source | 83,231,000Source | 72,711,000Source | 60,999,000Source | 55,485,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -188,462,000Source | -189,474,000Source | -146,322,000Source | 279,771,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | 1,700,000Source | 1,800,000Source | — |
| Investment Income, InterestUSD | — | — | 6,765,000Source | 9,603,000Source | — | 7,592,000Source | 3,643,000Source | 5,523,000Source | 28,329,000Source | 38,473,000Source | 42,247,000Source | 16,079,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -57,119,000Source | -51,107,000Source | -55,427,000Source | -34,727,000Source | -43,165,000Source | -45,621,000Source | -146,412,000Source | -162,857,000Source | -146,398,000Source | 158,519,000Source |
| Nonoperating Income (Expense)USD | — | — | 7,510,000Source | 31,031,000Source | 3,812,000Source | 13,241,000Source | 7,982,000Source | 9,676,000Source | 39,508,000Source | 114,371,000Source | 63,178,000Source | 22,588,000Source |
| Operating ExpensesUSD | — | — | 85,233,000Source | 100,170,000Source | 66,827,000Source | 66,669,000Source | 65,834,000Source | 66,895,000Source | 292,231,000Source | 343,599,000Source | 275,232,000Source | 268,913,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 11,300,000Source | 9,100,000Source | 9,500,000Source | 7,100,000Source |
| Research and Development ExpenseUSD | — | — | 55,028,000Source | 40,969,000Source | 45,987,000Source | 39,213,000Source | 46,662,000Source | 42,496,000Source | 186,829,000Source | 167,259,000Source | 175,658,000Source | 107,879,000Source |
| Selling and Marketing ExpenseUSD | — | — | 2,906,000Source | 3,135,000Source | — | 3,009,000Source | — | 2,842,000Source | — | 12,779,000Source | 14,180,000Source | 11,270,000Source |
| Selling, General and Administrative Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
d20959dex41.htm · 8-K · 2026-08-13
EX-4.1 3 d20959dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2026 AbCellera Biologics Inc. AbCellera Biologics Inc., a corporation incorporated under the Business Corporations Act (British Columbia) (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its reg…
Read attachment ↗d20959dex991.htm · 8-K · 2026-08-13
EX-99.1 5 d20959dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants August 12, 2026 VANCOUVER, British Columbia - AbCellera Biologics Inc. (Nasdaq: ABCL) (“AbCellera”) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warra…
Read attachment ↗